X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PEEL-224 is a small molecule nanoparticle for the treatment of cancer. The active molecule of PEEL-224 derives from camptothecin (SN22), a naturally occurring compound found in the Chinese Happy Tree. Peel Therapeutics has designed PEEL-224 to improve efficacy and less toxicity.
Lead Product(s): SN22
Therapeutic Area: Oncology Product Name: PEEL-224
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2022
Details:
SN22 (7-Ethylcamptothecin) is camptothecin derivative and newly engineered drug is made from multiple SN22 molecules reversibly linked to carrier fully eliminated by body after delivering its payload.Active constituent of PEEL-224 is SN22 used for treatment of childhood solid tumors.
Lead Product(s): SN22
Therapeutic Area: Oncology Product Name: SN22
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: CHOP
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2020
Details:
The scientists prevented NETs in healthy immune cells exposed to plasma from the blood of COVID-19 patients with the help of a natural NET inhibitor, discovered in newborn babies and is being developed by PEEL Therapeutics as a possible treatment for inflammation in COVID-19.
Lead Product(s): Neutrophil targeting peptide
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
